Repligen (RGEN) AI Stock Analysis

• Market Cap: $9.63B
• Dividend Yield: N/A
• Average Volume (3M): 933.91K
• Price to Earnings (P/E): 6654.5
• Beta (1Y): 0.99
• Revenue Growth: 11.74%
• EPS Growth: N/A
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.46
• Shares Outstanding: 56,290,750
• 10 Day Avg. Volume: 620,504
• 30 Day Avg. Volume: 933,914
• PEG Ratio: 1.84
• Price to Book (P/B): 4.08
• Price to Sales (P/S): 12.69
• P/FCF Ratio: 56.51
• Enterprise Value/Market Cap: 0.78
• Enterprise Value/Revenue: 10.59
• Enterprise Value/Gross Profit: 23.34
• Enterprise Value/Ebitda: 56.05
• 1Y Price Target: $181.20
• Price Target Upside: 8.93% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): 1.67
• Revenue Forecast (FY): $732.93M

• Rating: 68 Neutral
• Price Target: $182.00 ▲(9.41% Upside)

Repligen's overall stock score reflects strong earnings call performance and positive technical indicators, tempered by high valuation concerns. The company's financial performance is stable, with opportunities for improvement in profitability. The positive sentiment from the earnings call and technical momentum are significant strengths, while the high P/E ratio is a notable risk.

Positive Factors

Organic Growth

Strong organic growth across all franchises indicates robust demand for Repligen's products, supporting long-term revenue expansion and market position.

Geographical Expansion

Significant growth in Asia Pacific and other regions enhances Repligen's global footprint, diversifying revenue streams and reducing dependency on any single market.

Gross Margin Improvement

Improved gross margins reflect better cost management and operational efficiency, which can lead to sustained profitability and competitive pricing strategies.

Negative Factors

China Market Challenges

Challenges in the Chinese market could hinder growth prospects and affect revenue, given China's significant role in the global biopharmaceutical landscape.

Filtration Growth Constraints

Slower than expected growth in filtration may impact overall revenue growth, as this segment is crucial to Repligen's product offerings and market strategy.

Gene Therapy Platform Impact

The anticipated decline from a key gene therapy customer could affect short-term revenue, highlighting vulnerability to customer-specific demand fluctuations.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Repligen generates revenue through the sale of its bioprocessing products and solutions to pharmaceutical and biotechnology companies. The company's revenue model is primarily based on product sales, which include consumables, instruments, and systems used in the biomanufacturing process. Key revenue streams come from the sale of chromatography resins, filtration systems, and other essential bioprocessing technologies. Additionally, Repligen benefits from long-term partnerships with major pharmaceutical companies, which often involve supply agreements for its proprietary products. The company's focus on innovation and expanding its product portfolio, coupled with increasing demand for biologics, further contributes to its earnings.

Repligen Financial Statement Overview

Summary

Repligen demonstrates moderate financial health with growth in revenue and operational efficiency. The balance sheet is stable with manageable leverage, though profitability metrics like net profit margin and return on equity are areas for improvement. Cash flow generation is positive, supporting operational needs. Overall, the company is on a stable trajectory with opportunities to enhance profitability and cash flow efficiency.

Income Statement

Repligen's income statement shows moderate growth and profitability. The TTM (Trailing-Twelve-Months) revenue growth rate is 5.04%, indicating a recovery from previous declines. Gross profit margin improved to 47.90% TTM, reflecting efficient cost management. However, net profit margin remains low at 0.25% TTM, suggesting challenges in converting revenue into profit. EBIT and EBITDA margins have improved, indicating better operational efficiency.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 0.33 TTM, indicating manageable leverage. The equity ratio is healthy, suggesting a strong asset base. However, return on equity is low at 0.09% TTM, highlighting limited returns on shareholder investments. Overall, the balance sheet shows stability with room for improvement in profitability.

Cash Flow

Cash flow analysis reveals positive trends with a free cash flow growth rate of 1.66% TTM, indicating improved cash generation. The operating cash flow to net income ratio is nearly 1, suggesting good cash conversion. However, the free cash flow to net income ratio is 0.81 TTM, indicating some challenges in translating profits into free cash flow. Overall, cash flow management appears solid with potential for further optimization.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	707.89M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	321.25M	274.64M	278.44M	455.71M	391.25M	194.35M
EBITDA	133.76M	80.26M	145.32M	277.31M	203.27M	98.42M
Net Income	1.74M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.92B	2.83B	2.83B	2.53B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	748.75M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	688.87M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	840.62M	856.95M	866.34M	620.90M	608.29M	373.74M
Stockholders Equity	2.08B	1.97B	1.96B	1.91B	1.75B	1.53B
Cash Flow
Free Cash Flow	106.48M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	130.89M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-154.49M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-13.95M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 166.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 166.35 is above the 20-day moving average (MA) of 155.62, above the 50-day MA of 149.62, and above the 200-day MA of 134.43, indicating a bullish trend. The MACD of 5.76 indicates Negative momentum. The RSI at 61.19 is Neutral, neither overbought nor oversold. The STOCH value of 84.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	78 Outperform	$5.13B	44.32	8.30%	―	11.49%	-2.89%
RGEN	68 Neutral	$9.63B	6,654.47	0.08%	―	11.74%	―
STVN	67 Neutral	$6.37B	41.06	9.81%	0.27%	9.19%	23.06%
ATR	60 Neutral	$8.19B	19.99	15.80%	1.48%	2.50%	25.05%
TFX	60 Neutral	$4.83B	―	-7.90%	1.19%	5.43%	-245.18%
BLCO	56 Neutral	$5.73B	―	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Repligen Corporate Events

Repligen’s Q3 Earnings Call: Strong Growth and Positive Outlook

Repligen’s Q3 Earnings Call: Strong Performance and Positive Outlook

Repligen Corporation Reports Strong Q3 2025 Results

Repligen Corporation is a global life sciences company that specializes in developing and commercializing innovative bioprocessing technologies and systems, primarily serving biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs). The company is headquartered in Waltham, Massachusetts, with manufacturing sites in the U.S. and Europe.

Repligen Appoints Violetta Hughes as Chief Accounting Officer

On September 2, 2025, Repligen Corporation announced the appointment of Violetta Hughes as the new Chief Accounting Officer, effective September 1, 2025. This strategic move aims to enhance the company’s financial reporting infrastructure and compliance with the Sarbanes–Oxley Act. Ms. Hughes, a seasoned finance executive with over 25 years of experience, will replace Jason K. Garland, who will continue as the Chief Financial Officer focusing on corporate strategy and growth. Her extensive background in financial governance and SOX compliance is expected to bring significant improvements to Repligen’s financial transparency and strategic decision-making processes.

The most recent analyst rating on (RGEN) stock is a Buy with a $207.00 price target. To see the full list of analyst forecasts on Repligen stock, see the RGEN Stock Forecast page.